Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$79.22 - $105.37 $22.6 Million - $30 Million
284,886 Added 699.11%
325,636 $33.2 Million
Q1 2023

May 15, 2023

BUY
$30.85 - $93.17 $656,796 - $1.98 Million
21,290 Added 109.4%
40,750 $3.7 Million
Q3 2022

Nov 14, 2022

BUY
$19.41 - $36.49 $171,487 - $322,389
8,835 Added 83.15%
19,460 $489,000
Q4 2021

Feb 14, 2022

SELL
$25.61 - $110.96 $1,306 - $5,658
-51 Reduced 0.48%
10,625 $280,000
Q3 2021

Nov 15, 2021

SELL
$100.0 - $143.02 $11,900 - $17,019
-119 Reduced 1.1%
10,676 $1.07 Million
Q2 2021

Aug 16, 2021

BUY
$78.27 - $151.29 $207,885 - $401,826
2,656 Added 32.63%
10,795 $1.53 Million
Q1 2021

May 17, 2021

SELL
$94.25 - $132.81 $3.09 Million - $4.35 Million
-32,786 Reduced 80.11%
8,139 $811,000
Q4 2020

Feb 16, 2021

SELL
$102.03 - $184.62 $4.35 Million - $7.87 Million
-42,626 Reduced 51.02%
40,925 $5.06 Million
Q3 2020

Nov 16, 2020

BUY
$93.53 - $163.34 $2.94 Million - $5.13 Million
31,405 Added 60.23%
83,551 $8.14 Million
Q2 2020

Aug 14, 2020

SELL
$126.3 - $176.56 $3.1 Million - $4.33 Million
-24,521 Reduced 31.98%
52,146 $8.14 Million
Q1 2020

May 15, 2020

SELL
$124.16 - $247.74 $1.91 Million - $3.81 Million
-15,380 Reduced 16.71%
76,667 $11.1 Million
Q4 2019

Feb 14, 2020

BUY
$74.57 - $217.92 $6.28 Million - $18.3 Million
84,158 Added 1066.78%
92,047 $18.8 Million
Q2 2019

Aug 14, 2019

BUY
$77.72 - $94.35 $24,170 - $29,342
311 Added 4.1%
7,889 $744,000
Q1 2019

May 15, 2019

SELL
$51.9 - $101.79 $7,421 - $14,555
-143 Reduced 1.85%
7,578 $648,000
Q4 2018

Feb 14, 2019

BUY
$48.76 - $76.44 $24,916 - $39,060
511 Added 7.09%
7,721 $433,000
Q3 2018

Nov 14, 2018

BUY
$35.64 - $92.06 $39,702 - $102,554
1,114 Added 18.27%
7,210 $589,000
Q2 2018

Aug 14, 2018

BUY
$19.94 - $40.96 $121,554 - $249,692
6,096 New
6,096 $213,000

Others Institutions Holding RETA

About REATA PHARMACEUTICALS INC


  • Ticker RETA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,583,200
  • Description
  • Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...
More about RETA
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.